Table 2.

Rates and relative risks of viral suppression

		Rate of viral suppression			Adjusted*RR of viral suppression
		Clinic group	Hybrid group	Community group	Hybrid group versus clinic group		Community group versus clinic group
					RR (95% CI)	p value	RR (95% CI)	p value
Overall for South Africa and Uganda		269/426 (63%)	282/413 (68%)	306/414 (74%)	1·08 (0·98–1·19)	0·12; 0·0049†	1·18 (1·07–1·29)	0·0005
Gender overall		..	..	..	..	0·035‡	..	0·0067‡
	Men	120/221 (54%)	134/203 (66%)	156/213 (73%)	1·19 (1·02–1·40)	..	1·34 (1·16–1·55)	..
	Women	149/205 (73%)	148/210 (70%)	150/201 (75%)	0·98 (0·87–1·10)	..	1·04 (0·93–1·17)	..
Age overall, years		..	..	..	..	0·85‡	..	0·50‡
	18–29	98/144 (68%)	114/160 (71%)	116/154 (75%)	1·07 (0·92–1·24)	..	1·14 (0·98–1·31)	..
	≥30	171/282 (61%)	168/253 (66%)	190/260 (73%)	1·08 (0·96–1·23)	..	1·20 (1·07–1·35)	..
Site		..	..	..	..	0·21‡	..	0·16‡
	Southwestern Uganda	64/84 (76%)	66/91 (73%)	74/94 (79%)	0·97 (0·81–1·16)	..	1·06 (0·90–1·24)	..
	Midlands KwaZulu-Natal, South Africa	125/213 (59%)	137/216 (63%)	151/220 (69%)	1·08 (0·93–1·25)	..	1·17 (1·01–1·35)	..
	Northern KwaZulu-Natal, South Africa	80/129 (62%)	79/106 (75%)	81/100 (81%)	1·20 (1·01–1·42)	..	1·31 (1·11–1·55)	..
South Africa		205/342 (60%)	216/322 (67%)	232/320 (72%)	1·12 (1·00–1·25)	0·055; 0·0026†	1·22 (1·09–1·36)	0·0004
Gender for South Africa		..	..	..	..	0·037‡	..	0·015‡
	Men	91/178 (51%)	100/153 (65%)	113/158 (72%)	1·26 (1·04–1·51)	..	1·39 (1·17–1·66)	..
	Women	114/164 (70%)	116/169 (69%)	119/162 (73%)	0·99 (0·86–1·15)	..	1·07 (0·93–1·22)	..

Data are n (%) unless specified. Data are for the modified intention-to-treat population, overall and among subgroups. RR=relative risk.

^*Adjusted for gender, age younger than 30 years, baseline CD4 cell count (WHO category), and study site.

^†p value for a one-sided Wald test for non-inferiority (RR >0·95).

^‡p value for a Wald test for significant interaction.